Dynamics of pneumolysin in adults with pneumococcal pneumonia.

  • Research type

    Research Study

  • Full title

    Cohort study of pneumolysin and other cytokine profiles in patients with pneumococcal pneumonia

  • IRAS ID

    156106

  • Contact name

    WS Lim

  • Contact email

    weishen.lim@nuh.nhs.uk

  • Sponsor organisation

    Nottingham University Hopsitals NHS Trust

  • Duration of Study in the UK

    2 years, 0 months, 1 days

  • Research summary

    Research Summary
    Respiratory infections, including community acquired pneumonia, account for a large burden of disease worldwide. Streptococcus pneumoniae is the commonest cause of community acquired pneumonia. Over time, this organism is increasingly developing antibiotic resistance. Therefore, it is crucial to identify other targeted treatment strategies.
    Pneumolysin (PLY) is a toxin produced by most clinically relevant strains of S. pneumoniae. This toxin is crucial in the disease causing ability of the organism. A new anti-PLY treatment has been developed and tested in animals. However, to be able to develop this treatment for human use, as an adjunct to current treatment strategies, we need to understand the patterns of PLY released in clinical illness.
    This study proposes to characterise these patterns in detail.
    We aim to measure PLY levels in patients hospitalalised with pneumonia, both due to S. pneumoniae (cases) and also other organisms (controls) over 5 days from initial presentation. This will allow us to assess 1. trends in PLY concentration over time and at achivement of clinical stability and 2. association of PLY with disease severity. It will also allow us to correlate PLY concentrations with more commonly used markers of infection and inflammation e.g. cytokines and C-Reactive Peptide.
    Patients with community acquired pneumonia will be treated in the normal way by the doctors looking after them. All our study requires are blood tests, urine tests and if possible, sputum tests once a day for 5 days. The results of the tests will not affect patient care in any way.

    Summary of Results
    2 participants were recruited into the study. However, at this time, it was determined that the study assay could not validated, therefore samples were not processed and no further participants were recruited.

  • REC name

    East Midlands - Nottingham 1 Research Ethics Committee

  • REC reference

    14/EM/1285

  • Date of REC Opinion

    9 Jan 2015

  • REC opinion

    Further Information Favourable Opinion